The management of erectile dysfunction: Innovations and future perspectives

Archivio Italiano di Urologia e Andrologia

Volumn 83, Issue 1, 2011, Pages 60-62

  Leonardi, Rosario ^a   Alemanni, Matteo ^b  

^a Centro Regionale Veneto di Prevenzione Cura Ricerca ed Insegnamento per la Fibrosi Cistica   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Avanafil; Erectile dysfunction; Lodenafil carbonate; Sildenafil; SLx 2101; Tadalafil; Udenafil; Vardenafil; Vardenafil ODT

Indexed keywords

AVALAFIL; CYSTEINE; HYDROGEN SULFIDE; LODENAFIL; MIRODENAFIL; PHOSPHODIESTERASE INHIBITOR; RHO KINASE INHIBITOR; SILDENAFIL; SLX 2101; TADALAFIL; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

BACKACHE; CONFERENCE PAPER; DRUG COATING; DRUG MECHANISM; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; NOSE CONGESTION; PENIS ERECTION; SIDE EFFECT; SMOOTH MUSCLE CONTRACTION; VISUAL DISORDER;

ERECTILE DYSFUNCTION; FORECASTING; HUMANS; MALE; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 79956161654     PISSN: 11243562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunction in men. J Sex Med 2010; 7:3572.
2. Mehrotra N, Gupta M, Kovar A, et al. The role of pharmacokinetics and pharmacodynamics in phosphodiesterases inhibitor therapy, Int J Impot Res 2007; 19:253.
3. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitorsfor erectile dysfunction. J Clin Pharmacol 2005; 45:987.
4. Frances SH, Morris GZ, Corbin JD. Molecular mechanisms that could contribute to prolonged effectivenessof PDE5, inhibitors to improve erectile function. Int J Impot Res 2008; 20:333.
5. Porst H, Sharlip ID, Hatzichristou D, et al. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double blind, placebo-controlled study. Eur Urol 2006; 50:1086.
6. Shabsigh R, Kaufman J, Magee M, et al. Lack of awareness of erectile dysfunction in many men with risk factors for erectile dysfunction. BMC Urol 2010; 10:18.
7. Heinig R, Weimann B, Dietrich H, et al. Pharmakietics of a new orodispersible tablet formulation of vardenafil. Clin Drug Investig 2011; 31:27.
8. Sperling H, Debruyne F, Boermans A, et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010; 7:1497.
9. Gittelman M, McMahon CG, Rodrìguez-Rivera JA, et al. The POTENT II randomized trial: efficacy and safety of an orodispersible vardenafil formulationfor the treatment of erectile dysfunction. Int J Clin Pract 2010; 64:594.
10. Sperling H, Gittelman M, Norenberg C, et al. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. J Sex Med 2011; 8:261.
11. Nakamizo T, Kawamata J, Yoshida K, et al. Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J Neurosci Res 2003; 15:71.
12. Hannes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomydn-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am J Physiol Lung Cell Mol Physiol. 2008; 294:L24.
13. Eros D, Szántai-Kis C, Kiss R, Kéry, et al. Structure - activity relationships of PDE5 inhibitors. Curr Med Chem 2008; 15:1570.
14. Hatzmouratidis K, Hatzichristou DG. Looking to the future for erectile dysfunction therapies. Drugs 2008; 68:231.
15. Albersen M, Shindel AW, Mwamukonda KB, et al. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opin Emerging Drugs 2010; 15:467.
16. Palit V, Fardley I. An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. Nat Rev Urol 2010; 7:603.
17. Salem EA, Kendirci M, Hellstrom WJG. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 2006; 7:661.
18. Gur S, Sikka SC, Hellstrom WJG. Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drug 2008; 17:855.
19. Kim BH, Lim HS, Chung JY, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDES inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol 2008; 65:848.
20. Paick JS, Ahn TY, Choi HK et al. Efficay and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008; 5:2672.
21. Glina S, Fonseca GN, Bertero EB, et al. Efficay and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010; 7:1928.
22. Toque HA, Teixeira CE, Lorenzetti R, et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavemosum. Eu J Pharmacol 2008; 591:189.
23. Limin M, Johnsen N, Hellstrom WJG. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2010; 19:1427.
24. Jung J, Choi S, Cho SH, et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther 2010; 32:1178.
25. Liu WJ, Xin ZC, Xin H, et al. Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl 2005; 7:381.
26. Sousa CM, Havt A, Santos CF, et al. The relaxation induced by uroguanyllin and the expression of natriuretic peptide receptors in human corpora cavernosa. J Sex Med 2010; 7:3610.
27. Dai Y, Chitaley K, Webb RC, et al. Topical application of a Rhokinase inhibitor in rats causes penile erection. Int J Impot Res 2004; 16:294.
28. O'Sullivan SE. What is the significance of vascular hydrogen sulphide (H2S)? BrJ Pharmacol 2006; 149:609.
29. Srilatha B, Adaikan PG, Moore PK. Possible role of a novel gasotransmitter hydrogen sulphyde in erectile dysfunction - a pilot study. Eu J Pharmacol 2006; 535:280.
30. Bhatia M. Hydrogen sulfide as a vasodilator. IUBMB Life 2005; 57:603.